Development of Companion Diagnostics

Development of Companion Diagnostic Tests for New and Existing Therapeutic Compounds

Being able to stratify patients to qualify for use of a given drug is rapidly becoming as important as traditional pharmacological and toxicological properties of that drug. Skyline is your partner of choice to develop gene signature-based assays to identify patient groups with favorable drug response profiles. Development of these crucial companion diagnostics can start as early as in the preclinical stage and may extend into clinical phase 4 testing. Skyline’s extensive experience with all stages and aspects of diagnostics development ensures effective identification of relevant patient groups. Use of that knowledge by means of a Profiler will add significant value to your drug compound of interest, patented or generic. We prefer to collaborate in risk- and cost-sharing co-developments, but other deal models are open for discussion. If you are interested, we invite you to contact us.